Blog
RSS FeedPosted by Michael Wonder on 21 Feb 2023
ICER publishes final evidence report on treatments for multiple sclerosis
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...
Posted by Michael Wonder on 16 Feb 2023
ICER releases draft evidence report on treatments for non-alcoholic steatohepatitis
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom ...
Posted by Michael Wonder on 10 Feb 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee (February 2023)
10 February 2023 - The Health Technology Assessment Policy and Methods Review Reference Committee met on 27 January 2023. ...
Posted by Michael Wonder on 05 Feb 2023
Release of the Strengthening Medicare Taskforce Report
3 February 2023 - The Strengthening Medicare Taskforce Report is now available. ...
Posted by Michael Wonder on 23 Jan 2023
ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 13 Jan 2023
Public Summary Documents – September 2022 PBAC meeting
13 January 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the September 2022 PBAC ...
Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
Posted by Michael Wonder on 22 Dec 2022
Final report for the post-market review of medicines for smoking cessation and review outcomes
22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...
Posted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
Posted by Michael Wonder on 21 Dec 2022
PBS Expenditure and Prescriptions Report (2021-22)
21 December 2022 - The PBS Expenditure and Prescriptions Report 1 July 2021 to 30 June 2022 is now available. ...
Posted by Michael Wonder on 01 Dec 2022
ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
Posted by Michael Wonder on 18 Nov 2022
PBAC Public Summary Document (November 2022)
18 November 2022 - The Public Summary Documents for the Review of the base-case discount rate in the PBAC Guidelines from ...
Posted by Michael Wonder on 11 Nov 2022
Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 PBAC meeting
11 November 2022 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2022 PBAC ...
Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 28 Oct 2022
Public Summary Documents – July 2022 PBAC meeting
28 October 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2022 PBAC ...